Free Trial
NASDAQ:TNXP

Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Tonix Pharmaceuticals logo
$40.87 -1.49 (-3.52%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$40.66 -0.21 (-0.52%)
As of 07/11/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tonix Pharmaceuticals Stock (NASDAQ:TNXP)

Key Stats

Today's Range
$38.87
$42.25
50-Day Range
$18.84
$42.36
52-Week Range
$6.76
$130.00
Volume
612,208 shs
Average Volume
973,482 shs
Market Capitalization
$300.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$585.00
Consensus Rating
Buy

Company Overview

Tonix Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

TNXP MarketRank™: 

Tonix Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 487th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tonix Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Tonix Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($1,762.50) to ($541.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tonix Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tonix Pharmaceuticals has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tonix Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    16.46% of the float of Tonix Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tonix Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Tonix Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.46% of the float of Tonix Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tonix Pharmaceuticals has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tonix Pharmaceuticals has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Tonix Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 40 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
  • MarketBeat Follows

    Only 37 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,200.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.03% of the stock of Tonix Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tonix Pharmaceuticals' insider trading history.
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings
See More Headlines

TNXP Stock Analysis - Frequently Asked Questions

Tonix Pharmaceuticals' stock was trading at $32.98 at the beginning of 2025. Since then, TNXP shares have increased by 23.9% and is now trading at $40.87.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings results on Monday, May, 12th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($3.23) by $0.39. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.55 million. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative trailing twelve-month return on equity of 120.96%.

Shares of Tonix Pharmaceuticals reverse split on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

Last Earnings
5/12/2025
Today
7/12/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TNXP
CIK
1430306
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$1,100.00
Low Price Target
$70.00
Potential Upside/Downside
+1,331.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1,963.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$130.04 million
Net Margins
-1,313.87%
Pretax Margin
-1,313.87%
Return on Equity
-120.96%
Return on Assets
-101.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.31
Quick Ratio
11.64

Sales & Book Value

Annual Sales
$10.09 million
Price / Sales
29.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$31.82 per share
Price / Book
1.28

Miscellaneous

Outstanding Shares
7,360,000
Free Float
7,355,000
Market Cap
$300.80 million
Optionable
Not Optionable
Beta
2.05

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TNXP) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners